A Phase I Study of BGB-16673 in People with B Cell Cancers


Full Title

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies


In this study, researchers are seeking to find the highest dose of the investigational drug BGB-16673 that can be given safely in people with lymphoma and other types of B cell cancers that have come back or continued to grow despite prior treatment. BGB-16673 degrades a protein called BTK, which helps B cells live and grow. By degrading BTK, BGB-16673 may stop or slow the growth and activity of B cells, which could lead to improvement in the symptoms associated with B cell cancers. BGB-16673 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, or Waldenstrom’s macroglobulinemia that has come back or continued to grow despite previous treatment.
  • The serious side effects of prior therapies must go away before taking BGB-16673.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information about this study and to ask about eligibility, please contact the office of Dr. Meghan Thompson at 646-608-4253.




Phase I/II (phases 1 and 2 combined)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID